MedTrace Logo

Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

NCT03394885 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-08-12

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.

Conditions

Interventions

DRUG

Atezolizumab

1200mg IV q3weeks

DRUG

Carboplatin

5-6mg/ML IV q3 weeks

DRUG

Paclitaxel

70-80 mg/m2 IV q1 week

DRUG

Bevacizumab

15 mg/kg IV q3 weeks

Sponsors & Collaborators

Principal Investigators

  • Angeles A Secord, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-19
Primary Completion
2020-07-20
Completion
2020-07-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03394885 on ClinicalTrials.gov